[{"address1": "5750 Explorer Drive", "address2": "Suite 404", "city": "Mississauga", "state": "ON", "zip": "L4W 0A9", "country": "Canada", "phone": "905-602-5840", "website": "https://www.cipherpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig J. Mull", "title": "Interim CEO & Chairman of the Board", "fiscalYear": 2022, "totalPay": 78348, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Jacobs", "title": "Chief Financial Officer", "fiscalYear": 2022, "totalPay": 293349, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Diane  Gajewczyk", "title": "Vice President of Scientific & Medical Affairs", "fiscalYear": 2022, "totalPay": 238398, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Emilio  Presti", "title": "Director of Sales & Marketing", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.53, "open": 6.4937, "dayLow": 6.4937, "dayHigh": 6.63, "regularMarketPreviousClose": 6.53, "regularMarketOpen": 6.4937, "regularMarketDayLow": 6.4937, "regularMarketDayHigh": 6.63, "beta": 1.038, "trailingPE": 8.25, "forwardPE": 13.2, "volume": 11708, "regularMarketVolume": 11708, "averageVolume": 21337, "averageVolume10days": 7750, "averageDailyVolume10Day": 7750, "marketCap": 159108176, "fiftyTwoWeekLow": 2.2, "fiftyTwoWeekHigh": 7.37, "priceToSalesTrailing12Months": 7.5185795, "fiftyDayAverage": 6.0602, "twoHundredDayAverage": 4.2975, "currency": "USD", "enterpriseValue": 118861688, "profitMargins": 0.96319, "floatShares": 22567829, "sharesOutstanding": 24107300, "sharesShort": 11427, "sharesShortPriorMonth": 48425, "sharesShortPreviousMonthDate": 1477872000, "dateShortInterest": 1480464000, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.44513, "heldPercentInstitutions": 0.01121, "shortRatio": 0.97, "impliedSharesOutstanding": 24227900, "bookValue": 3.357, "priceToBook": 1.966041, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": -0.611, "netIncomeToCommon": 20383000, "trailingEps": 0.8, "forwardEps": 0.5, "enterpriseToRevenue": 5.617, "enterpriseToEbitda": 10.39, "52WeekChange": 1.7208333, "SandP52WeekChange": 0.22379243, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CPHRF", "underlyingSymbol": "CPHRF", "shortName": "CIPHER PHARMACEUTICALS INC", "longName": "Cipher Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1138890600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "33ee6a68-9bd5-3305-98c7-75445d99f34d", "messageBoardId": "finmb_8201659", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.6, "recommendationKey": "none", "totalCash": 39825000, "totalCashPerShare": 1.66, "ebitda": 11440000, "totalDebt": 353000, "quickRatio": 8.552, "currentRatio": 9.191, "totalRevenue": 21162000, "debtToEquity": 0.438, "revenuePerShare": 0.846, "returnOnAssets": 0.080579996, "returnOnEquity": 0.28192, "freeCashflow": 5478750, "operatingCashflow": 15999000, "earningsGrowth": -0.604, "revenueGrowth": 0.002, "grossMargins": 0.80772, "ebitdaMargins": 0.54059, "operatingMargins": 0.48150003, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]